Dermatology

Adults with severe alopecia were shown to have statistically significant efficacy across 2 phase 3 clinical studies highlighted in this announcement.

Following this pooled analysis, there may be a need for additional research conducted to identify other targets for achievement of optimal repigmentation.

In this exclusive deep dive, a pair of leading dermatologists highlight the new data defining ruxotitinib cream, upadacitinib, and more agents from the revolutionary drug class.

These findings suggest that those with atopic dermatitis exacerbations may need to limit their oral corticosteroid duration for the purposes of limiting AEs.

In this Q&A interview, Stein Gold discusses new phase 3 findings regarding ruxolitinib cream 1.5% for patients 2 to 11 years old with atopic dermatitis.

A phase 2 trial showed cendakimab, an IL-13 inhibitor, reduced Eczema Area and Severity Index scores in moderate to severe atopic dermatitis patients.

In this interview, Rosmarin discussed the results of a new post-hoc analysis of the TRuE-V1 and TRuE-V2 studies on treating younger vitiligo patients with ruxolitinib cream.

A study found omega-3 supplements and a Mediterranean diet improved acne severity and quality of life in patients without prescription meds.

In this analysis, investigators highlighted the results of treating psoriasis with deucravacitinib in the phase 3 POETYK PSO-1 and PSO-2 trials.

These data suggest the necessity of additional research to explore seborrheic dermatitis as well as its variations among many diverse groups and populations.

In this post-hoc analysis, investigators highlighted benefits of deucravacitinib among those with psoriasis compared to benefits of apremilast.

These data highlight the determinants and risk factors for admission to hospital among individuals with dermatological emergencies.

This decision by FDA officials resulted from the INTEGUMENT study findings which determined that once-daily roflumilast led to rapid eczema clearance and significant disease reductions.

These findings also highlighted the necessity of identifying the clinically relevant comorbidities of asthma and allergic rhinitis in a proactive manner.

Arcutis Biotherapeutics announced the update and indicated the FDA was working to finalize the action letter on July 09, 2024, which was 2 days after the assigned PDUFA date of July 07, 2024.

These findings confirm the ways in which patient responses in the head and neck areas contribute to modifications in life quality among those with eczema.

After a busy first half to 2024, a number of high-impact FDA decisions await the healthcare industry through December.

This retrospective study highlighted the results of Singaporean atopic dermatitis patients aged 18 years and below who had undergone phototherapy.

Raj Chovatiya, MD, PhD, MSCI, and Lawrence Eichenfield, MD, review a recent trial comparing upadacitinib to dupilumab for patients with atopic dermatitis.

This analysis from Spain assessed the short-term effectiveness and safety of abrocitinib within a real-world setting for those with moderate-to-severe eczema.

Our dermatology FDA recap for the first half of 2024 includes our top 5 approvals, 3 decisions to watch in the second half of 2024, and a podcast episode with James Del Rosso, DO

This analysis explores the burden level in pediatric and adolescent eczema patients within Japan, highlighting associated burden on caregivers/families and other factors.

These findings were referenced by skincare brand CeraVe, highlighting the need for skin health education as well as skin health barriers.

These data suggest differences in Medicaid-accepting pediatric dermatologist access based on such factors as geographic area and density of pediatric dermatologists per county.

This summary of major dermatology news covered in June highlights stories such as late-breaking data at RAD 2024, recent interviews, and recent FDA news.